This protocol induces an obese, hyperglycemic, insulin-resistant phenotype that models key features of human T2D; in contrast, the same STZ dose does not cause hyperglycemia in insulin-sensitive, chow-fed controls [16,17]. Here, INS is linked to type 2 diabetes mellitus.